Board of Directors
Jeffrey Arnold, Chairman, is the president of Arnold Strategies, LLC, a strategic advisor to early and growth stage CEOs, and an angel investor with Mass. Med. Angels and Boston Harbor Angels. As an investor, he has invested in, among others, SmartCells (sold to Merck), BioAssets development Corp (sold to Cephalon), Syntonix (sold to Biogen Idec), Health Honors (sold to Healthway) and JB Therapeutics (now public as Corbus Pharmaceutical Holdings). Prior to founding Arnold Strategies, he spent 20 years as the CEO of multiple private and public technology and life science companies. Among these include Cambridge Heart, a cardiology diagnostics company which he founded and took public, CardioFocus, a VC backed catheter ablation company and Accelrys, a public company with software tools for rational drug design, now a division of Dassault Systèmes. Mr. Arnold is a guest lecturer at the MIT Sloan School, mentor at the MIT Venture Mentoring Society, on the Grant Review Board of the MIT Deshpande Center and on the Board of Overseers at the Museum of Science. He was formerly Chairman of the Greater Boston Chapter of the American Heart Association. He received a BSEE from MIT in 1972.
Thierry Bernard, Director, is the Senior Vice President at QIAGEN, in the Molecular Diagnostics Business Area, a growing presence in diagnostic solutions for healthcare. Mr. Bernard joined the QIAGEN team in February 2015 from bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Boards of Directors of three privately held U.S. companies, AdvanDx, HepatoChem and more recently, Daktari Diagnostics, where he also served as CEO. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe and is a member of French Foreign Trade Advisors.
Dr. Sal Salamone, Director, is the founder of Saladax Biomedical which is a company dedicated to the development of Therapeutic Drug Management (TDM) assays in the field of oncology and companion diagnostics. Saladax has launched numerous TDM oncology drug assays and supported clinical studies on their effective use. Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax he was Senior Vice President of R&D at Orasure Technologies where he developed rapid point of care tests in the infectious disease and drugs of abuse areas. Before Orasure he was Vice President of Research and Development at Roche Diagnostics, where he was responsible for North American research and development efforts for the Laboratory Systems Division. Dr. Salamone’s efforts during his 17-year tenure at Roche resulted in the launch of seven major reagent product lines, comprised of more than 70 FDA approved products and more than 200 instrument applications. Dr. Salamone is well published in the field with more than 70 peer reviewed publications, numerous book chapters and is also the holder of 42 issued US patents. He serves on the boards of several companies, is a reviewer for several scientific journals, participates on NIH study sections for SBIR-STTR grants and often is an invited speaker at major conferences. Dr. Salamone received two bachelor’s degrees from Villanova University, a master’s and a PhD degree from Rutgers University and was a SERC Post-Doctoral Fellow at Oxford University.
Don Straus is Director, CEO, CSO, and founder of First Light Biosciences. Don previously founded Rapid Micro Biosystems, a commercialization-stage venture-backed company, at which he served as a Director. He also founded Rapid Micro’s predecessor, Genomic Profiling Systems. Don served as VP of Research at these companies for 9 years. At both First Light and Rapid Micro he identified the target markets, invented the core scientific technology, built the founding teams, developed the initial product concepts, led IP development, and managed development of the initial product prototypes. His prior research experience includes projects in molecular and microbial detection technologies, genomics, molecular biology, enzymology, and developmental biology. Don was Assistant Professor of Biology at Brandeis University, did post-doctoral work at Massachusetts General Hospital, earned a doctorate in Biochemistry and Molecular Biology from Harvard University, and received a B.S. in Chemistry from University of California, Berkeley.
Norm Gitis, Board Observer, obtained his Ph.D. (1983) in Mechanical Engineering from the USSR Academy of Sciences in Moscow. He immigrated to the US in 1989 and was a visiting professor at MIT until IBM moved him to San Jose, where he worked in the computer industry. Norm was founder, President, and CEO of two highly-profitable test-instrumentation companies. Both have been acquired by leading corporations with high multiples. He was twice named the CEO of Top 20 Fastest Growing Private Companies in Northern California by the Business Journal. Norm is a life member of the engineering society of India and is a visiting professor of two universities in China. Norm has authored over 150 scientific papers, three books, and two dozen patents. He also chaired and organized numerous international scientific conferences. In parallel, Norm has been active in IP and product quality protection and has been a star expert witness in courts of Amsterdam, Berlin, Boston, London, Phoenix, and San Jose. Norm serves on the Board of Directors of Life Science Angels, where he also chairs a med-device committee, and two med-tech stealth-mode start-ups in the oncology and cardiology spaces.